Fulvestrant, Ipatasertib and CDK4/6 Inhibition in Metastatic ER+/HER2- Breast Cancer Patients Without ctDNA Suppression
Fulvestrant, Ipatasertib and CDK4/6 Inhibition in Metastatic ER+/HER2- Breast Cancer Patients Without ctDNA Suppression
Active, not recruiting · NCT04920708 · Registry updated 2026-04-14Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Fulvestrant, Ipatasertib and CDK4/6 Inhibition in Metastatic ER+/HER2- Breast Cancer Patients Without ctDNA Suppression | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, estrogen-receptor positive breast cancer, neoplasm, skin disorder | Active, not recruiting | Phase 2 | 2026-04-14 | NCT04920708 |
3 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Hoffmann-La Roche | 280 |
| Pfizer | 431 |
| Royal Marsden NHS Foundation Trust | 89 |
13 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Addenbrookes Hospital | Cambridge | United Kingdom | 3 |
| Beatson West of Scotland Cancer Centre | Glasgow | United Kingdom | 18 |
| Imperial College University Hospitals NHS Trust | London | United Kingdom | 1 |
| Mount Vernon Cancer Centre | London | United Kingdom | 2 |
| Nottingham City Hospital | Nottingham | United Kingdom | 19 |
| Oxford University Hospitals | Oxford | United Kingdom | 2 |
| Royal Cornwall Hospital | Truro | United Kingdom | 2 |
| Royal Free Hospital | London | United Kingdom | 2 |
| Royal Marsden NHS Foundation Trust | London | United Kingdom | 11 |
| The Christie NHS Foundation Trust | Manchester | United Kingdom | 113 |
| University College London Hospital | London | United Kingdom | 32 |
| Velindre Cancer Centre | Cardiff | United Kingdom | 4 |
| Western General Hospital | Edinburgh | United Kingdom | 52 |